Stop TB Partnership

Dong-A gains WHO prequalification for supply of second-line TB drug

16 November - Seoul, Republic of Korea - Dong A, a pharmaceutical manufacturer has been prequalified by the World Health Organization (WHO) for the manufacture and supply of cyloserine, a second-line anti-tuberculosis (TB) drug.

The prequalification makes Dong A eligible to supply cyloserine through the Stop TB Partnership’s Global Drug Facility (GDF), pending a bid-evaluation review which will be completed in early December.